Insight

Treatment-related hearing loss in medulloblastoma – TCH Pediatric Hematology Oncology Fellowship

Photo taken from TCH Pediatric Hematology Oncology Fellowship/X

Aug 2, 2024, 09:40

Treatment-related hearing loss in medulloblastoma – TCH Pediatric Hematology Oncology Fellowship

TCH Pediatric Hematology Oncology Fellowship shared on X:

“Findings in Neuro-Oncology (Oxford Academic) byand colleagues reveal for medulloblastoma that a patient’s age and the radiation dose to the cochlea inner ear are key risk factors for treatment-related hearing loss.”

The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma

Autors: Mohammad H Abu-Arja, Austin L Brown, Jack M Su, M Fatih Okcu, Holly B Lindsay, Susan L McGovern, Mary Frances McAleer, David R Grosshans, Murali M Chintagumpala, Arnold C Paulino

Treatment-

Source: TCH Pediatric Hematology Oncology Fellowship/X

Arnold C Paulino Austin L Brown cancer David R Grosshans Holly B Lindsay Jack M Su M Fatih Okcu Mary Frances McAleer medulloblastoma Mohammad Abu-Arja Murali M Chintagumpala Neurology OncoDaily Oncology Susan L McGovern TCH Pediatric Hematology Oncology Fellowship

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage